Prof. Dr. med. Dr. med. habil. Olaf G Wilhelm
Chief Executive Officer and Chairman of the Executive Management Board
Prof. Dr. med. Olaf G. Wilhelm is founder and Chief Executive Officer of Therawis Pharma GmbH, Munich. He also was co-founder of Wilex Biotechnology GmbH and its Managing Director from October 1, 1997 until April 8, 2001, and has been Chief Executive Officer of WILEX AG since April 9, 2001 since the conversion of the company into a stock market corporation (Wilex AG). Prof. Wilhelm managed two company acquisitions, several international development and commercialization partnerships and listed Wilex AG on the public stock Exchange. In the year 2001, he was appointed Extraordinary Professor of Gynecology at the Technical University of Munich. From 1990 to 1997, he was employed as senior physician for Obstetrics and Gynecological Oncology at the Dept. Obstetrics & Gynecology (Frauenklinik) at the Medical School of the university hospital Klinikum rechts der Isar des Klinikums rechts der Isar) at the Technical University of Munich. While at the Technical University of Munich, Prof. Wilhelm was also a member of the Clinical Research Unit of the Frauenklinik. From 1987 to 1990, he worked as a scientist for Eli Lilly and Company, Indianapolis, Indiana/USA. Prof. Wilhelm received the Midwest Trainee Award of the American Federation for Clinical Research and has authored over 70 publications. He received his MD from the Technical University of Munich. Prof. Wilhelm is a member of the senate of the “Bundeswirtschaftssenat des Bundesverbandes mittelständische Wirtschaft Deutschland e.V.” In 2011, the Technical University of Munich awarded him the title “TUM Entrepreneur of Excellence”.
Prof. Dr. rer. nat. Dr. med. habil. Manfred Schmitt
Chief Scientific Officer
Manfred Schmitt is a biochemist and cell biologist by training (Johannes Gutenberg University, Mainz, Germany) and a tenured professor emeritus at the Medical School of the Technical University of Munich, Germany. As a full professor of Experimental Gynecology, from 1987 to 2015, he has headed the Clinical Research Unit of the Department of Obstetrics and Gynecology at the university hospital Klinikum rechts der Isar. During that time, he supervised translational research in the area of gynecological oncology and gestational diseases as a focus of the department. Manfred Schmitt was a member of the Translational Research Advisory Committee of the EORTC, Brussels, and has been the chairman of the PathoBiology Group of the EORTC for six years. He is still cooperating within a trans-European and trans-world network regarding cancer biomarkers as tools for patient diagnosis, prognosis, disease monitoring, and therapy response, also with foreign bodies such as AACR, ASCO, NCI, FDA, and the WIN consortium. Since 1989, Manfred Schmitt has been coordinator or partner in publically funded national (e.g. DFG, BMBF, Wilhelm-Sander Foundation, German Cancer Aid) and EU-funded projects (ESPRIT-3, TMR, Marie Curie, 4th Medical and Health, Biomed-1, Biomed-2, FP6/FP7) with focus on therapy response/resistance markers in cancer. He is board member of the Henner-Graeff Foundation, of the Frey-Werle Foundation, and the breast cancer foundation PATH. He is member of the Scientific Advisory Board of WIN (Worldwide Innovative Networking Consortium in personalized cancer medicine). He is listed as a co-inventor on 75 patents and has published >420 articles in international scientific journals or books.
Dr. rer. nat. Gabriele Schricker
Director Project Management
Dr. Gabriele Schricker, Director Project Management at Therawis Diagnostics GmbH, has a broad background of more than seventeen years of professional experience in international project management and information & documentation management in the field of drug development. Dr. Schricker started her professional career at a clinical CRO for 3 years and worked during the last 14 years for 6 biopharmaceutical companies in Germany, Switzerland, and Italy. She was mainly responsible for partnered co-development alliances and projects with focus in oncology (small molecules and biologics) and inflammatory diseases (biologics) leading multi-disciplinary and multi-cultural drug development teams in early to late stage development programs. In addition, she was responsible for financial and program reporting to internal and external governance committees, supervisory boards, and key stakeholders. Furthermore, Dr. Schricker has a strong expertise in implementation and optimization of project management processes, team performance, and communication. Dr. Schricker holds a PhD in Biology from the University of Cologne, Germany. After her PhD thesis in Zoology, she gained a second qualification in Scientific Information Management and earned additional qualifications in coaching and psychological counselling. Dr. Schricker is keynote speaker for project management at the European Centre for Regulatory Affairs (EUCRAF, Freiburg) since 2011.
Dr. rer. nat. Rudolf Napieralski
Manager Research & Development
Dr. Rudolf Napieralski, Manager Research & Development, is also co-founder of Therawis Diagnostics GmbH and is a chemist by training. Rudolf worked previously more than ten years in translational cancer research and several years in commercial biomarker development and genomics services. He gained significant expertise in molecular biology, translational tumor biomarker development, especially for quantitative PCR assays, cancer epigenetics and signal transduction pathways. Rudolf completed an advanced training program “Life Science management” at the ATV GmbH, Munich, gaining insight into business development processes, project management, QC and QA, health care regulations and marketing. His research at the department of obstetrics and gynecology and the Institute of Pathology, Technical University of Munich, focused on conducting and managing clinical tumor biomarker development in national and international clinical trials. Rudolf’s industrial career included positions as Manager R&D for the development of single cell qRT-PCR assays at the GILUPI GmbH and Project Assistant at Eurofins Genomics GmbH (formerly Eurofins Medigenomics GmbH). Dr. Napieralski earned his PhD in Biochemistry in the field of adenosine mediated signal transduction pathways from the Institute of Anthropology and Human Genetics at the Ludwig Maximilians University, Munich.